Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2023; 15(6): 1005-1018
Published online Jun 15, 2023. doi: 10.4251/wjgo.v15.i6.1005
Published online Jun 15, 2023. doi: 10.4251/wjgo.v15.i6.1005
5’tiRNA-Pro-TGG, a novel tRNA halve, promotes oncogenesis in sessile serrated lesions and serrated pathway of colorectal cancer
Xin-Yuan Wang, Yu-Jie Zhou, Hai-Ying Chen, Jin-Nan Chen, Hui-Min Chen, Xiao-Bo Li, Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, China
Shan-Shan Chen, Department of Spleen and Stomach and Rheumatology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Author contributions: Li XB was the guarantor of the paper; Wang XY and Chen SS collected clinical samples and performed the experiments; Chen HY analyzed data; Wang XY and Zhou YJ wrote the original draft; Chen JN revised the manuscript; Li XB and Chen HM conceived and supervised the study; All the authors revised and approved the final manuscript.
Supported by the Program of Health and Family Planning Research Project Plan of Pudong New Area Health Committee , No. PW2020D-12 .
Institutional review board statement: This study was approved by Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee, No. KY2021-004.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Bo Li, PhD, Chief Doctor, Chief Physician, Professor, Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, No. 145 Middle Shandong Road, Shanghai 200000, China. lxb_1969@163.com
Received: February 1, 2023
Peer-review started: February 1, 2023
First decision: February 16, 2023
Revised: February 27, 2023
Accepted: April 17, 2023
Article in press: April 17, 2023
Published online: June 15, 2023
Processing time: 133 Days and 18.5 Hours
Peer-review started: February 1, 2023
First decision: February 16, 2023
Revised: February 27, 2023
Accepted: April 17, 2023
Article in press: April 17, 2023
Published online: June 15, 2023
Processing time: 133 Days and 18.5 Hours
Core Tip
Core Tip: Our study identified the transfer RNA-derived small RNAs expression profile of sessile serrated lesions (SSLs) for the first time and found that tRNA halves (tiRNAs)-1:33-Pro-TGG-1, which was associated with polyp size, were highly expressed in SSLs and promoted oncogenesis in colorectal cancer cell. Furthermore, tiRNA-1:33-Pro-TGG-1 potentially promotes the progression of serrated pathway colorectal cancer (CRC) through metabolic and immune pathways by interacting with HPSE2 in SSLs and BRAF mutant CRC. In the future, tiRNA-1:33-Pro-TGG-1 may serve as a potential target for the early diagnosis of SSLs and treatment of CRC that arises from the serrated pathway.